Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Multiple Dose Study of SPH3127 in Healthy Chinese Subjects
NCT03255993Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sitokiren in hypertension (HTN) (6 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: Number of participants with adverse events (AEs). Started Oct 2017; status: completed.
02
Drugs
sitokiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03255993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255993.